Definium Therapeutics — Third Quarter 2026 Earnings Summary

Definium Therapeutics reported positive topline results from two Phase 3 studies, Voyage and Panorama, for its DT120 ODT drug in treating generalized anxiety disorder, meeting all primary and secondary efficacy endpoints. The company also received FDA Breakthrough Therapy designation for DT120 ODT in major depressive disorder following successful Phase 3 Emerge study results and announced positive initial findings from a Phase 2a trial of DT402 in adults with autism spectrum disorder. Financially, the company held approximately $1.05 billion in cash, cash equivalents, and investments as of September 30, 2026, with a net loss of $51.0 million for the third quarter of 2026. Definium Therapeutics remains on track to file a New Drug Application for DT120 ODT in the first half of 2027.